NRAS and acute myeloid leukemia: The most common molecular event in the AML patient cohort was a TET2 (50.5%) mutation, followed by ASXL1 (19.1%), CEBPA (17.2%), FLT3-ITD (16.3%), DNMT3A (13.5%), NRAS (12.0%), NPM1 (11.1%), RUNX1 (7.7%), IDH1 (6.8%), and IDH2 (6.8%) mutations (Table 4).